In the News - Avilar Therapeutics

April 05, 2023

Targeted Protein Degradation: A Promising Option for Cancer Drug Developers

Genetic Engineering & Biotechnology News: Instead of inhibiting disease-causing proteins, targeted protein degraders consign them to proteosomal and endolysosomal pathways.

February 22, 2023

Exclusive: Sanofi, Astellas venture arms add cash to Avilar’s ‘ATAC’ mission

Endpoints News: The venture arms of Sanofi and Astellas have grown their investment in Avilar Therapeutics to help steer the biotech through a niche of the growing protein degradation field.

February 15, 2023

Asked and Answered–Damian Doherty Chats With Effie Tozzo, PhD, Chief Scientific Officer of Avilar Therapeutics

Inside Precision Medicine: Taking Protein Degradation to a New Therapeutic Frontier—Outside the Cell

December 07, 2022

Effie Tozzo, PhD, Avilar Therapeutics’ Chief Scientific Officer, Named to the Endpoints News List of Top Women in Biopharma R&D

December 7, 2022 – We are proud to announce today that Avilar’s Chief Scientific Officer, Effie Tozzo, PhD, has been named to the Endpoints News list of top women in biopharma research and development in 2022. Each year since 2019, Endpoints News has spotlighted twenty extraordinary women who have blazed trails at the upper echelons […]

November 18, 2022